Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial-Reference-Cited by-同舟云学术

Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial

Published:2021-09 Issue: Volume:154 Page:21-29
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Guarneri Valentina^ORCID,Giorgi Carlo Alberto^ORCID,Cinieri Saverio^ORCID,Bengala Carmelo,Mariani Gabriella,Bisagni Giancarlo,Frassoldati Antonio,Zamagni Claudio,De Rossi Costanza,Amoroso Vito^ORCID,Andreetta Claudia,Ferro Antonella,Zambelli Alberto,Gori Stefania,Garrone Ornella^ORCID,Dieci Maria Vittoria^ORCID,Orlando Laura,Pastina Ilaria,Beninato Teresa,Moretti Gabriella^ORCID,Genovesi Elisa,Cinefra Margherita,Vicini Roberto^ORCID,Magni Giovanna^ORCID,De Salvo Gian L.^ORCID,Conte PierFranco^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5);Cardoso;Ann Oncol,2020

3. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of Clinical Oncology Guideline;Rugo;J Clin Oncol,2016

4. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium;Lobbezoo;Ann Oncol,2016

5. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients;Jacquet;Eur J Cancer,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

2. Reporting on invasive lobular breast cancer in clinical trials: a systematic review;npj Breast Cancer;2024-03-20

3. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond;Expert Review of Anticancer Therapy;2024-03-18

4. Advances in the regulatory mechanisms of mTOR in necroptosis;Frontiers in Immunology;2023-12-18

5. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA);The Breast;2023-12